Novo Nordisk Price to Book Ratio 2010-2024 | NVO

Historical price to book ratio values for Novo Nordisk (NVO) over the last 10 years. The current price to book ratio for Novo Nordisk as of September 19, 2024 is 37.28.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Novo Nordisk Price/Book Ratio Historical Data
Date Stock Price Book Value per Share Price to Book Ratio
2024-09-20 127.51 inf
2024-06-30 142.20 0.00
2024-03-31 127.91 0.00
2023-12-31 102.32 $3.43 29.82
2023-09-30 89.95 0.00
2023-06-30 79.65 0.00
2023-03-31 78.33 0.00
2022-12-31 66.10 $2.59 25.50
2022-09-30 48.66 0.00
2022-06-30 54.13 0.00
2022-03-31 53.95 0.00
2021-12-31 53.89 $2.44 22.12
2021-09-30 46.20 0.00
2021-06-30 40.09 0.00
2021-03-31 32.27 0.00
2020-12-31 32.98 $2.06 15.98
2020-09-30 32.79 0.00
2020-06-30 30.68 0.00
2020-03-31 28.20 0.00
2019-12-31 26.75 $1.80 14.87
2019-09-30 23.89 0.00
2019-06-30 23.38 0.00
2019-03-31 23.97 0.00
2018-12-31 21.11 $1.62 13.05
2018-09-30 21.60 0.00
2018-06-30 20.93 0.00
2018-03-31 22.35 0.00
2017-12-31 23.95 $1.55 15.47
2017-09-30 21.49 0.00
2017-06-30 18.94 0.00
2017-03-31 15.14 0.00
2016-12-31 15.53 $1.34 11.56
2016-09-30 18.01 0.00
2016-06-30 23.06 0.00
2016-03-31 23.23 0.00
2015-12-31 24.47 $1.37 17.84
2015-09-30 22.85 0.00
2015-06-30 23.07 0.00
2015-03-31 22.50 0.00
2014-12-31 17.57 $1.39 12.68
2014-09-30 19.77 0.00
2014-06-30 19.17 0.00
2014-03-31 18.95 0.00
2013-12-31 15.05 $1.38 10.92
2013-09-30 13.79 0.00
2013-06-30 12.63 0.00
2013-03-31 13.16 0.00
2012-12-31 13.04 $1.25 10.40
2012-09-30 12.61 0.00
2012-06-30 11.61 0.00
2012-03-31 11.08 0.00
2011-12-31 9.05 0.00
2011-09-30 7.81 0.00
2011-06-30 9.84 0.00
2011-03-31 9.83 0.00
2010-12-31 8.71 0.00
2010-09-30 7.62 0.00
2010-06-30 6.27 0.00
2010-03-31 5.97 0.00
2009-12-31 4.85 0.00
2009-09-30 4.78 0.00
2009-06-30 4.14 0.00
2009-03-31 3.65 0.00
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $605.278B $33.708B
Bagsv?rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care and Biopharmaceuticals. While the Diabetes and obesity care segment covers insulins, glucagon-like peptide 1 (GLP-1), other protein-related products, obesity and oral anti-diabetic drugs, the Biopharmaceuticals segment includes hemophilia, growth hormone therapy and hormone replacement therapy.Novo Nordisk's most well-known drugs include Levemir, NovoRapid, Victoza, Ozempic, NovoMix, NovoSeven, NovoThirteen, Ryzodeg, Xultophy, Saxenda, Rybelsus, Esperoct, Sogroya and Norditropin, among several others. The company launched its first product for weight management, Saxenda, in the United States in 2015.In August 2018, Novo Nordisk announced that it has acquired all of the shares of Ziylo Ltd.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $869.678B 100.66
Johnson & Johnson (JNJ) United States $396.762B 15.73
AbbVie (ABBV) United States $341.999B 18.09
Merck (MRK) United States $296.921B 18.01
AstraZeneca (AZN) United Kingdom $244.635B 21.80
Novartis AG (NVS) Switzerland $237.063B 16.47
Pfizer (PFE) United States $168.074B 21.97
Sanofi (SNY) $147.557B 13.97
Innoviva (INVA) United States $1.231B 6.83